Inactive Instrument

Ambrx Biopharma Inc. Nasdaq

Equities

AMAM

US02290A1025

Biotechnology & Medical Research

Ambrx Biopharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2022

August 29, 2022 at 04:05 pm EDT

Ambrx Biopharma Inc. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was USD 2.91 million compared to USD 5.13 million a year ago. Net loss was USD 51.49 million compared to USD 29.01 million a year ago.

Basic loss per share from continuing operations was USD 1.33 compared to USD 11.41 a year ago.

Latest news about Ambrx Biopharma Inc.

Ambrx Biopharma Inc. Announces Resignation of Andrew Aromando as Chief Operating Officer	Mar. 12	CI
Johnson & Johnson Completes Ambrx Acquisition	Mar. 07	MT
J&J: completes $2 billion acquisition of Ambrx Biopharma	Mar. 07	CF
Ambrx Biopharma Inc.(NasdaqGS:AMAM) dropped from NASDAQ Composite Index	Mar. 06	CI
Johnson & Johnson completed the acquisition of Ambrx Biopharma Inc. from a group of shareholders.	Mar. 06	CI
Ambrx Biopharma Inc.(NasdaqGS:AMAM) dropped from S&P Global BMI Index	Mar. 06	CI
Ambrx Biopharma Shareholders Approve Johnson & Johnson Acquisition Deal	Mar. 06	MT
Ambrx Biopharma Inc.(NasdaqGS:AMAM) dropped from NASDAQ Biotechnology Index	Mar. 05	CI
J&J's Acquisition of Ambrx Biopharma Completes Hart-Scott-Rodino Waiting Period	Feb. 22	MT
Sanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion -- Update	Jan. 23	DJ
North American Morning Briefing : Central Bankers -2-	Jan. 17	DJ
North American Morning Briefing : Focus Fixed on -2-	Jan. 11	DJ
JMP Securities Downgrades Ambrx Biopharma to Market Perform From Market Outperform	Jan. 10	MT
Global markets live: Boeing, GSK, Hays, Shell, Eli Lilly...	Jan. 09
B. Riley Downgrades Ambrx Biopharma to Neutral From Buy on Heels of Announced Sale to Johnson & Johnson, Adjusts PT to $28 From $26	Jan. 09	MT
Health Care Up as Merger Wave Continues -- Health Care Roundup	Jan. 08	DJ
Sector Update: Health Care Stocks Rise Late Afternoon	Jan. 08	MT
News Highlights : Top Company News of the Day - Monday at 3 PM ET	Jan. 08	DJ
Trending : Johnson & Johnson and Merck & Co. Announce Acquisitions	Jan. 08	DJ
Sector Update: Health Care Stocks Rise in Afternoon Trading	Jan. 08	MT
Top Midday Gainers	Jan. 08	MT
News Highlights : Top Company News of the Day - Monday at 1 PM ET	Jan. 08	DJ
BTIG Downgrades Ambrx Biopharma to Neutral From Buy	Jan. 08	MT
News Highlights : Top Company News of the Day - Monday at 11 AM ET	Jan. 08	DJ
Drugmakers kick off industry conference with two cancer deals	Jan. 08	RE

Chart Ambrx Biopharma Inc.

Duration

Period

More charts

Company Profile

Ambrx Biopharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its ADC targeting Human epidermal growth factor receptor 2 (HER2). It uses genetic code technology platform to discover and develop engineered precision biologics. Its genetic code technology platform allows to incorporate, in a site-specific manner, synthetic amino acids (SAA), into proteins within living cells. Its SAA incorporation technology is designed to develop a range of product candidate modality, such as modified cytokines and bispecific antibodies, and others.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research